IGFBP6
Insulin-like growth factor-binding protein 6
Also known as: IBP6_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P24592
- Gene
- IGFBP6
- Ensembl
- ENSG00000167779
- Chromosome
- 12
- Canonical length
- 240 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
Enables identical protein binding activity and insulin-like growth factor II binding activity. Involved in cell migration and positive regulation of stress-activated MAPK cascade. Part of insulin-like growth factor binary complex. Implicated in obesity. Biomarker of breast cancer; in situ carcinoma; leiomyoma; and neovascular inflammatory vitreoretinopathy. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
240 residues, UniProt reviewed canonical sequence.
>P24592|IGFBP6
1 MTPHRLLPPL LLLLALLLAA SPGGALARCP GCGQGVQAGC PGGCVEEEDG GSPAEGCAEA
61 EGCLRREGQE CGVYTPNCAP GLQCHPPKDD EAPLRALLLG RGRCLPARAP AVAEENPKES
121 KPQAGTARPQ DVNRRDQQRN PGTSTTPSQP NSAGVQDTEM GPCRRHLDSV LQQLQTEVYR
181 GAQTLYVPNC DHRGFYRKRQ CRSSQGQRRG PCWCVDRMGK SLPGSPDGNG SSSCPTGSSGLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IGFBP6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.53
- Highest tissue expression
- 787 nTPM
Expression across tissuesHPA
Tissue
- blood vessel: 787 nTPM
- cervix: 552 nTPM
- fallopian tube: 529 nTPM
- vagina: 512 nTPM
- breast: 395 nTPM
- adipose tissue: 354 nTPM
Single-cell type
- fibroblasts: 2,166 nCPM
- decidual stromal cells: 1,550 nCPM
- peritubular myoid cells: 1,382 nCPM
- leydig cells: 721 nCPM
- pericytes: 663 nCPM
- hepatic stellate cells: 633 nCPM
Immune cell
- eosinophil: 32 nTPM
- non-classical monocyte: 20 nTPM
- naive CD8 T-cell: 6.9 nTPM
- intermediate monocyte: 6.8 nTPM
- memory CD8 T-cell: 5.4 nTPM
- MAIT T-cell: 3.4 nTPM
Brain region
- choroid plexus: 108 nTPM
- thalamus: 46 nTPM
- spinal cord: 33 nTPM
- hypothalamus: 25 nTPM
- pons: 24 nTPM
- basal ganglia: 24 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.92
- gnomAD pLI
- 0.03
- gnomAD missense Z
- 0.23
- DepMap mean gene effect
- -0.11
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell migration
- negative regulation of canonical Wnt signaling pathway
- negative regulation of cell population proliferation
- positive regulation of MAPK cascade
- positive regulation of stress-activated MAPK cascade
- regulation of insulin-like growth factor receptor signaling pathway
- signal transduction
Molecular functions
- fibronectin binding
- identical protein binding
- insulin-like growth factor I binding
- insulin-like growth factor II binding
- signaling receptor binding
Cellular components
- extracellular region
- extracellular space
- insulin-like growth factor binary complex
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of IGFBP6 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IGFBP6 as an antibody target. Whether an autoantibody or antibody against IGFBP6 could matter depends on whether native IGFBP6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IGFBP6 is annotated as secreted, so native IGFBP6 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label IGFBP6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...